Since its founding in 2006, the CERN Foundation has been committed to improving the care and outcome of people with ependymoma through community support and research efforts. Today, we are excited to share that our support of research and patient and caregiver participation in the research have made a significant impact.

The key findings of the research studies, which focus on the role of chemotherapy for recurrent ependymoma and genetic and environmental risk factors among adult ependymoma patients, were presented at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO), held November 15 to 18, 2018, in New Orleans. The meeting had a record attendance of 2,400 registrants and CERN was honored to be among them. A synopsis of the research findings shared at SNO is provided in this summary.

Thank you, immensely, patients, caregivers and families, for your participation over the past 13 years. It is you who have made these findings possible.

READ MORE